Reprint
Biosimilars in Europe
Edited by
February 2023
188 pages
- ISBN978-3-0365-6575-0 (Hardback)
- ISBN978-3-0365-6574-3 (PDF)
This is a Reprint of the Special Issue Biosimilars in Europe that was published in
Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary
This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.
Format
- Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
infliximab; etanercept; TNFα inhibitors; biologics; biosimilars; Germany; policies; incentives; uptake; market dynamics; biosimilar market; biosimilar/supply and distribution; biosimilar sustainability; Delphi technique; biosimilars; pricing; reimbursement; utilization; biosimilar; biological; information; education; communication; patient; Europe; adalimumab; biosimilar; biosimilarity assessment; quality attributes (QAs); potentially critical quality attributes (pCQAs); European public assessment reports (EPARs); incentives; clinical governance; biosimilars; Spain; barriers; biosimilars; regulatory; review; approval; clinical; queries; regulatory science; biologics; biosimilars; budget impact analysis; savings; pharmaceutical spending; cost containment; Spain; biosimilar; reference biological; competitive market; Belgium; trastuzumab; biosimilar; intravenous; subcutaneous; HER2-positive breast cancer; drug costs; healthcare costs; cost simulation; tender; procurement; off-patent; biological; biosimilar; award criteria; switching; interchangeability; sustainability; competition; n/a